Rifaximin decreases virulence of Crohn’s disease-associated Escherichia coli and epithelial inflammatory responses

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of antibiotics (Tokyo. 1968)

• Publication date

  2018-02-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41429-017-0022-yPMID 29410518
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of antibiotics for treatment of inflammatory bowel disease.

  2016cited by this paper
• Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach

  2015cited by this paper
• Inflammation-associated Adherent-invasive Escherichia coli Are Enriched in Pathways for Use of Propanediol and Iron and M-cell Translocation

  2014cited by this paper
• Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity.

  2014cited by this paper
• Rifaximin: beyond the traditional antibiotic activity

  2014cited by this paper
• Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis

  2013cited by this paper
• Multidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohn's Disease

  2013cited by this paper
• Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.

  2012cited by this paper
• Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.

  2012cited by this paper
• Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps

  2012cited by this paper
• Inflammation Drives Dysbiosis and Bacterial Invasion in Murine Models of Ileal Crohn’s Disease

  2012cited by this paper
• Replication of Crohn's disease-associated AIEC within macrophages is dependent on TNF-α secretion

  2012cited by this paper
• Pregnane X receptor as a target for treatment of inflammatory bowel disorders.

  2012cited by this paper
• Biologic properties and clinical uses of rifaximin

  2011cited by this paper
• Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells

  2011cited by this paper
• Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei.

  2010cited by this paper
• Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles

  2009cited by this paper
• Microflora in Crohn’s disease: the emergence of adherent and invasive Escherichia coli

  2008cited by this paper
• Crohn's disease‐associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin

  2008cited by this paper
• Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells

  2008cited by this paper
• Effects of Rifaximin on Bacterial Virulence Mechanisms at Supra- and Sub-Inhibitory Concentrations

  2008cited by this paper
• Microbial influences in inflammatory bowel diseases.

  2008cited by this paper
• The Oxidoreductase DsbA Plays a Key Role in the Ability of the Crohn's Disease-Associated Adherent-Invasive Escherichia coli Strain LF82 To Resist Macrophage Killing

  2007cited by this paper
• Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

  2007cited by this paper
• Rifaximin Is a Gut-Specific Human Pregnane X Receptor Activator

  2007cited by this paper
• OmpC and the σE regulatory pathway are involved in adhesion and invasion of the Crohn's disease‐associated Escherichia coli strain LF82

  2007cited by this paper
• CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease.

  2007cited by this paper
• Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum

  2007cited by this paper
• The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease.

  2006influential reference
• Adherent and Invasive Escherichia coli Is Associated with Granulomatous Colitis in Boxer Dogs

  2006cited by this paper
• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

  2006cited by this paper
• Rifaximin: a novel antimicrobial for enteric infections

  2005cited by this paper
• Strong Decrease in Invasive Ability and Outer Membrane Vesicle Release in Crohn's Disease-Associated Adherent-Invasive Escherichia coli Strain LF82 with the yfgL Gene Deleted

  2005cited by this paper
• HtrA Stress Protein Is Involved in Intramacrophagic Replication of Adherent and Invasive Escherichia coli Strain LF82 Isolated from a Patient with Crohn's Disease

  2005cited by this paper
• Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes.

  2004influential reference
• Involvement of Lipoprotein NlpI in the Virulence of Adherent Invasive Escherichia coli Strain LF82 Isolated from a Patient with Crohn's Disease

  2004cited by this paper
• High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease.

  2004cited by this paper
• Regulatory and functional co‐operation of flagella and type 1 pili in adhesive and invasive abilities of AIEC strain LF82 isolated from a patient with Crohn's disease

  2003cited by this paper
• Effects of Rifaximin Administration on the Intestinal Microbiota in Patients with Ulcerative Colitis

  2002cited by this paper
• Adherent Invasive Escherichia coli Strains from Patients with Crohn's Disease Survive and Replicate within Macrophages without Inducing Host Cell Death

  2001cited by this paper
• In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration

  2000cited by this paper

• Effect of Fecal Microbiota Transplant on Antibiotic Resistance Genes Among Patients with Chronic Pouchitis

  2025cites this paper
• A Randomized Controlled Trial Of Antibiotics Targeting Adherent And Invasive Escherichia Coli (Aiec) Vs Placebo In Crohn's Disease: The Teorem Trial.

  2025cites this paper
• Research Progress on Rifaximin in Modulating Gut Microbiota for the Treatment of Nonalcoholic Fatty Liver Disease

  2025cites this paper
• Identification of Virulence Genes Associated with Pathogenicity of Translocating Escherichia coli with Special Reference to the Type 6 Secretion System

  2024cites this paper
• Therapeutic potential of rifaximin in liver diseases.

  2024cites this paper
• Construction of gene subgroups of Crohn disease based on transcriptome data

  2023cites this paper
• The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review

  2023cites this paper
• Rifaximine spacer application is not superior to local teicoplanin treatment in a rat model of osteomyelitis

  2022cites this paper
• Rifaximin protects SH‐SY5Y neuronal cells from iron overload‐induced cytotoxicity via inhibiting STAT3/NF‐κB signaling

  2022cites this paper
• Role of adherent invasive Escherichia coli in pathogenesis of inflammatory bowel disease

  2022cites this paper
• Bioinformatis analysis reveals possible molecular mechanism of PXR on regulating ulcerative colitis

  2021cites this paper
• Probing gut‐brain links in Alzheimer's disease with rifaximin

  2021cites this paper
• Rifaximin-Mediated Gut Microbiota Regulation Modulates the Polarization of Microglia During CUMS in Rat

  2021cites this paper
• Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.

  2021cites this paper
• Antimicrobial Resistance Profiles of Adherent Invasive Escherichia coli Show Increased Resistance to β-Lactams

  2020cites this paper
• Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.

  2020cites this paper
• Adherent-Invasive E. coli: Update on the Lifestyle of a Troublemaker in Crohn’s Disease

  2020cites this paper
• Genetic and Phenotypic Features to Screen for Putative Adherent-Invasive Escherichia coli

  2019cites this paper